Preclinical News and Research

RSS

Promising technique for treating eye disease proves effective in preclinical studies

A promising technique for treating human eye disease has proven effective in preclinical studies and may lead to new treatments to prevent blindness, according to experiments conducted at The Scripps Research Institute in La Jolla, California.

23 Oct 2013

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.

22 Oct 2013

Angiochem initiates ANG1005 Phase 2 study in patients with recurrent high-grade glioma

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in patients with recurrent high-grade glioma.

22 Oct 2013

Pancreatic cancer patients may benefit from antibody-drug conjugates

Patients with pancreatic cancer may benefit from an investigational member of an emerging class of anticancer drugs called antibody-drug conjugates, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

22 Oct 2013

Two drug combinations may provide new treatment option for patients with pancreatic cancers

Two drug combinations that simultaneously block two major signaling pathways downstream of the protein KRAS, which is aberrantly active in most pancreatic cancers, may provide a new treatment option for patients with this disease, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

22 Oct 2013

Astrazeneca, Evotec Launch Kidney Disease Collaboration

...

21 Oct 2013

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

21 Oct 2013

EntreMed presents preclinical data for ENMD-2076 in triple-negative breast cancer

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today the presentation of preclinical data from a study to assess the role of p53 family tumor suppressors in mediating response to ENMD-2076 in triple-negative breast cancer (TNBC).

21 Oct 2013

New investigational drug offers potential treatment option for lung cancer

PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

21 Oct 2013

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Inovio Pharmaceuticals, Inc. announced today that the safety, tolerability and immunogenicity of its therapeutic vaccine for hepatitis C (INO-8000/VGX-6150) will be studied in a phase I clinical trial in chronically HCV infected patients.

21 Oct 2013

Cell Therapeutics presents preclinical study results of PIXUVRI at AACR-NCI-EORTC meeting

Cell Therapeutics, Inc. (CTI) today announced the presentation of findings from a preclinical study of PIXUVRI® (pixantrone) that suggest its mechanism of inducing tumor cell death is novel and distinct from that of anthracyclines such as doxorubicin.

21 Oct 2013

New small-molecule inhibitor shows promising results in drug-resistant melanoma, breast cancer

LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23.

21 Oct 2013

Researchers identify key therapeutic target for cancers driven by KRAS protein

Patients with cancers driven by the protein KRAS, which are particularly hard to treat, may benefit from small molecules that attach to and disrupt the function of a KRAS-containing protein complex, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

20 Oct 2013

Research Institute receives Fast Track status for its gene therapy product for treatment of SMA

AveXis and BioLife, synthetic biology platform companies, today announced that The Research Institute at Nationwide Children's Hospital received Fast Track designation from the U.S. Food and Drug Administration for its scAAV9.CB.SMN gene therapy product for the treatment of spinal muscular atrophy (SMA).

19 Oct 2013

Five Research Units established to uncover physiological basis for cognitive processes, cultural techniques

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing five new Research Units. This was decided by the DFG Senate at its October meeting. The purpose of the research collaborations is to offer researchers the possibility to pursue current, pressing issues in their subject areas and to establish innovative work directions.

19 Oct 2013

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

...

18 Oct 2013

UC Irvine's 90+ Study to continue for another five years

UC Irvine's trailblazing 90+ Study, launched in 2003 to learn more about the "oldest old," the fastest-growing age group in the U.S., will continue for at least another five years, thanks to a $9.5 million renewal grant from the National Institute on Aging.

18 Oct 2013

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

...

17 Oct 2013

Pieris Inks Co-Development Alliance With Zydus For Protein Drugs

...

16 Oct 2013

SAGE Therapeutics obtains $20M Series B financing from two investors

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat central nervous system (CNS) diseases, today announced a $20 million Series B financing from investors ARCH Venture Partners and Third Rock Ventures, bringing the total raised to $57.8 million since launch in 2011.

16 Oct 2013

Preclinical News and Research

Promising technique for treating eye disease proves effective in preclinical studies

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

Angiochem initiates ANG1005 Phase 2 study in patients with recurrent high-grade glioma

Pancreatic cancer patients may benefit from antibody-drug conjugates

Two drug combinations may provide new treatment option for patients with pancreatic cancers

Astrazeneca, Evotec Launch Kidney Disease Collaboration

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

EntreMed presents preclinical data for ENMD-2076 in triple-negative breast cancer

New investigational drug offers potential treatment option for lung cancer

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Cell Therapeutics presents preclinical study results of PIXUVRI at AACR-NCI-EORTC meeting

New small-molecule inhibitor shows promising results in drug-resistant melanoma, breast cancer

Researchers identify key therapeutic target for cancers driven by KRAS protein

Research Institute receives Fast Track status for its gene therapy product for treatment of SMA

Five Research Units established to uncover physiological basis for cognitive processes, cultural techniques

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

UC Irvine's 90+ Study to continue for another five years

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

Pieris Inks Co-Development Alliance With Zydus For Protein Drugs

SAGE Therapeutics obtains $20M Series B financing from two investors

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics